Sastasundar ventures has disclosed a share acquisition by its promoter under SEBI insider trading regulations. The company informed BSE and NSE about the transaction through a formal disclosure on 16.02.2026.

Promoter Share Acquisition Details

Promoter Banwari Lal Mittal acquired additional equity shares of the company through market purchase. The transaction was executed on 11.02.2026 and intimated to the company on the same date.

Transaction Summary

The market purchase involved 8,000 equity shares with a total transaction value of Rs. 24,13,008.89, inclusive of taxes. This acquisition represents a strategic increase in the promoter's stake in the company.

Regulatory Compliance

The disclosure was made pursuant to Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. Company Secretary and Compliance Officer Pratap Singh submitted the required Form C to both BSE (Stock Code: 533259) and NSE (Symbol: SASTASUNDR).

The company confirmed that no derivative trading was involved in this transaction, with all derivative-related fields marked as "N.A." in the regulatory filing. The acquisition strengthens the promoter's position in Sastasundar Ventures Limited while maintaining full regulatory compliance.

Sastasundar Ventures Limited conducted its Q3FY26 earnings conference call on February 9, 2026, showcasing strong operational momentum across its B2B and B2C healthcare platforms. The company demonstrated significant improvement in financial metrics while advancing its technology-driven growth strategy.

Financial Performance Highlights

The company delivered robust financial results for Q3FY26, reflecting improved operational efficiency and sustained customer engagement across both business verticals.

For the nine-month period ended FY26, the company reported revenue of Rs. 928 crores, reflecting 15% year-on-year growth driven by steady performance across core segments. Gross profit increased 30% year-on-year to Rs. 70 crores, while gross margin improved by 80 basis points to 7.5% compared to 6.7% in the corresponding period last year.

Business Model and Strategic Positioning

Chairman and Executive Director B.L. Mittal emphasized the company's capital-efficient model, highlighting that total investment for futuristic technology remains less than treasury income, maintaining positive cash flow. The company operates through two key platforms: Retailer Shakti for B2B distribution and SastaSundar B2C for direct consumer engagement.

Technology and Infrastructure Expansion

The company continues investing in AI-enabled platforms to enhance customer experience and supply chain efficiency. Management announced the upcoming launch of Retail Air, an AI-driven SaaS platform that will be provided free to retailers for inventory management and automated ordering.

Warehouse Expansion Plans:

• West Bengal: Additional 80,000 square feet capacity with Rs. 10 crores investment
• Noida: New 1 lakh square feet warehouse under development
• Lucknow and Udaipur: New facilities planned for broader geographic coverage
• Guwahati: Expansion of existing Northeast operations

JITO Brand Launch and Market Strategy

The company launched its JITO brand for generic medicine distribution, leveraging its network of 65,000 retail pharmacies. Management expects JITO to contribute 2-3% of revenue in the next year, scaling to 5% within 24 months and targeting 10% contribution over the next 3-4 years. The JITO brand offers gross margins of approximately 30% with contribution margins around 25%.

Profitability Trajectory and Guidance

CFO Lokesh Agarwal highlighted the significant turnaround in profitability metrics. The company reported PAT of Rs. 11 crores for nine months FY26 compared to a loss of Rs. 151 crores in the corresponding period last year. Management confirmed that Retailer Shakti achieved EBITDA positive performance in January 2026 and expects sustainable profitability going forward.

Key Profitability Milestones:

• Retailer Shakti: EBITDA breakeven by Q4 FY26, sustainable positive performance in FY27
• SastaSundar B2C: Contribution margin positive achieved in January 2026
• Overall business: Targeting 30% CAGR growth for next 5-10 years

Corporate Restructuring and Future Plans

Management provided updates on the planned merger and demerger process. The company will change its name to Health X Platform Limited and merge SastaSundar HealthBuddy Limited while demerging Microsec Resources as a separate NBFC entity. The restructuring is expected to complete in the next financial year, subject to regulatory approvals and maintaining required public shareholding norms.